Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SARS CoV 2 vaccine inactivated - Sinovac Biotech

Next Previous
Drug Profile

SARS CoV 2 vaccine inactivated - Sinovac Biotech

Alternative Names: Adsorbed COVID-19 Vaccine inactivated - Sinovac; Coronavac; CoronaVac COVID-19 Vaccine (Vero Cell), Inactivated - Sinovac Biotech; CoronaVac®; COVID-19 vaccine - Sinovac Biotech; COVID-2019 vaccine - Sinovac Biotech; PiCoVacc; SARS-CoV-2 inactivated vaccine

Latest Information Update: 26 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovac Biotech
  • Developer PT Bio Farma; Sinovac Biotech
  • Class COVID-19 vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 31 May 2023 Sinovac completes a phase-III clinical trials in COVID-2019 infections (In infants, In children, In adolescents, Prevention) in Malaysia, Philippines, Chile, South Africa (IM)(NCT04992260)
  • 03 Feb 2023 Turkish Medicines and Medical Devices Agency approves CoronaVac® for treatment of COVID-19 infections (Children) in Turkey
  • 27 Jan 2023 Sinovac Biotech completes a phase III trial in COVID-2019 infections (In children, Prevention) in China (IM) (NCT05137418)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top